Cytotoxic T-lymphocyte associated protein 4 (redirect from Ctla4)
CD86 on the surface of antigen-presenting cells. It is encoded by the gene CTLA4 in humans. The CTLA-4 protein is encoded by the Ctla-4 gene in mice. CTLA-4...
30 KB (3,464 words) - 22:51, 24 May 2024
lymphocyte-associated protein 4 (CTLA4). CTLA4 is an immune effector molecule that acts as an inhibitory checkpoint for the immune response. CTLA4 resides in intracellular...
10 KB (1,110 words) - 18:19, 30 March 2023
and CTLA4 are very homologous and compete for the same ligand – CD80 and CD86. CTLA4 binds CD80 and CD86 always stronger than CD28, which allows CTLA4 to...
22 KB (2,834 words) - 03:10, 29 September 2024
with anti-CTLA4 therapeutics have emerged as important tumor treatments within the field of checkpoint inhibition. A combination of PD1 and CTLA4 antibodies...
39 KB (5,010 words) - 05:27, 17 August 2024
metastatic hormone-refractory prostate cancer. The concept of using anti-CTLA4 antibodies to treat cancer was first developed by James P. Allison while...
48 KB (4,684 words) - 06:38, 18 September 2024
ipilimumab, a CTLA4 blocker approved in the United States in 2011. Currently approved checkpoint inhibitors target the molecules CTLA4, PD-1, and PD-L1...
21 KB (2,093 words) - 02:41, 1 September 2024
multiple types of cancers. Currently approved checkpoint inhibitors block CTLA4, PD-1 and PD-L1. For the related basic science discoveries, James P. Allison...
31 KB (3,467 words) - 01:27, 25 June 2024
(e.g., immune checkpoint inhibitors like anti-PD1, anti-PDL1, and anti-CTLA4 agents) to treat sarcomas. These drugs are not yet FDA- or other regulator-approved...
37 KB (4,087 words) - 23:54, 14 August 2024
PMID 28983798. Hoos A (April 2016). "Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations". Nature Reviews. Drug Discovery. 15 (4):...
59 KB (6,128 words) - 05:06, 8 July 2024
Cancer therapy by inhibition of negative immune regulation (CTLA4, PD1)...
15 KB (1,518 words) - 23:23, 16 July 2024